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Background
Simplification of the administration of HAART in chil-
dren should improve compliance and efficacy of these
treatments. Combination of 3TC + DDI + EFV in a single
daily oral administration is one option. However, phar-
macokinetics, tolerance and efficacy of such once-a-day
HAART have not been assessed in children. The ANRS
12103 trial is a phase II on pharmacokinetics, tolerance
and compliance of a once-a-day pediatric DDI+3TC+EFV
in Burkina Faso.
Material and methods
ANRS 12103 is an ongoing Open Phase II Trial with a 12
months follow up. 50 HIV-1 infected children eligible for
HAART had to be included. Inclusion criteria were: weight
≥ 10 kg and aged 30 months to 15 years, naive of ARV
treatment and eligible for HAART. Children received efa-
virenz + 3TC (8mg/kg) + DDI (240mg/m2). Clinical
examination was performed weekly until M3, then
monthly. Pharmacokinetics (plasma Cmin and Cmax)
was done at day 15. Quaterly RNA HIV-1, CD4 counts,
haematology and biochemistry are performed.
Results
Enrolment was from February to November 2006 and 98
HIV-infected children have been screened for eligibility
criteria: 45 were excluded, one died before inclusion and
52 were included. Among included children there was 21
girls and 31 boys, mean age was 6.8 years, Zscore Weight
for Age (W/A) and Height for Age (H/A) were respectively
-1.91 and -1.99 at inclusion. Mean CD4 was 355/µl
(mean CD4 percentage 9%), and median HIV-1 RNA 5.50
Log10 cp/ml. Among the 52 expected samples for mini-
mum concentration of efavirenz, 50 were obtained. Thirty
children were in the expected ranges (60.1%), 11 (22%)
below therapeutic levels and 9 (18%) above therapeutic
levels. Maximum concentrations were in the expected
ranges in 23/49 children (47%), below therapeutic levels
in 3/49 children (6%) and over in 23/49 children. Dos-
ages of 3TC and DDI are ongoing.
At 9 months of follow-up, two children had died, Zscore
W/A and H/A were respectively -1.37 and -1.62, and mean
CD4 was 893/µl (mean CD4 percentage 20%). HIV-1
RNA was below detectable level (300 copies/ml) in 39
children (76%) and below 1000 copies/ml in two chil-
dren (4%).Two HAART adverse effect occurred. One cuta-
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neous eruption with a temporary stop and successful
reintroduction and one increase in liver enzymes.
Conclusion
Preliminary data of this phase II trial suggest that once-a-
day DDI+3TC+EFV in children provides satisfactory
plasma concentration for EFV, and is associated with viro-
logical success and immune restoration. At 9-month fol-
low up, it is effective and well tolerated.Page 2 of 2
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